title: Status of New Vaccine Introduction - Worldwide, September 2016.
abstract: Since the global Expanded Program on Immunization (EPI) was launched in 1974, vaccination against six diseases (tuberculosis, polio, diphtheria, tetanus, pertussis, and measles) has prevented millions of deaths and disabilities (1). Significant advances have been made in the development and introduction of vaccines, and licensed vaccines are now available to prevent 25 diseases (2,3). Historically, new vaccines only became available in low-income and middle-income countries decades after being introduced in high-income countries. However, with the support of global partners, including the World Health Organization (WHO) and the United Nations Children's Fund, which assist with vaccine prequalification and procurement, as well as Gavi, the Vaccine Alliance (Gavi) (4), which provides funding and shapes vaccine markets through forecasting and assurances of demand in low-income countries in exchange for lower vaccine prices, vaccines are now introduced more rapidly. Based on data compiled in the WHO Immunization Vaccines and Biologicals Database* (5), this report describes the current status of introduction of Haemophilus influenzae type b (Hib), hepatitis B, pneumococcal conjugate, rotavirus, human papillomavirus, and rubella vaccines, and the second dose of measles vaccine. As of September 2016, a total of 191 (99%) of 194 WHO member countries had introduced Hib vaccine, 190 (98%) had introduced hepatitis B vaccine, 132 (68%) had introduced pneumococcal conjugate vaccine (PCV), and 86 (44%) had introduced rotavirus vaccine into infant vaccination schedules. Human papillomavirus vaccine (HPV) had been introduced in 67 (35%) countries, primarily targeted for routine use in adolescent girls. A second dose of measles-containing vaccine (MCV2) had been introduced in 161 (83%) countries, and rubella vaccine had been introduced in 149 (77%). These efforts support the commitment outlined in the Global Vaccine Action Plan (GVAP), 2011-2020 (2), endorsed by the World Health Assembly in 2012, to extend the full benefits of immunization to all persons.
authors.forename: Anagha
authors.initials: A
authors.lastname: Loharikar
authors.forename: Laure
authors.initials: L
authors.lastname: Dumolard
authors.forename: Susan
authors.initials: S
authors.lastname: Chu
authors.forename: Terri
authors.initials: T
authors.lastname: Hyde
authors.forename: Tracey
authors.initials: T
authors.lastname: Goodman
authors.forename: Carsten
authors.initials: C
authors.lastname: Mantel
mesh_terms: D000293:Adolescent; D016667:Bacterial Capsules; D002648:Child; D002675:Child, Preschool; D005260:Female; D014943:Global Health; D018073:Haemophilus Vaccines / Q000008:administration & dosage; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D006801:Humans; D017589:Immunization Programs / Q000458:organization & administration*; D007115:Immunization Schedule; D007223:Infant; D007231:Infant, Newborn; D008458:Measles Vaccine / Q000008:administration & dosage; D053918:Papillomavirus Vaccines / Q000008:administration & dosage; D022242:Pneumococcal Vaccines / Q000008:administration & dosage; D022243:Rotavirus Vaccines / Q000008:administration & dosage; D012411:Rubella Vaccine / Q000008:administration & dosage; D014611:Vaccination / Q000706:statistics & numerical data*; D018074:Vaccines, Conjugate / Q000008:administration & dosage
chemical_list: D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D017325:Hepatitis B Vaccines; D008458:Measles Vaccine; D053918:Papillomavirus Vaccines; D022242:Pneumococcal Vaccines; D022243:Rotavirus Vaccines; D012411:Rubella Vaccine; D018074:Vaccines, Conjugate